Trial reportBMC nephrology2021
Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial.
Trial report in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Effect of carnosine or beta-alanine supplementation therapy for prediabetes or type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.BMC endocrine disorders · 2025Pooled it
- Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Trial
- β-alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial.Obesity (Silver Spring, Md.) · 2025Trial
- Trial
- Considerations for Carnosine Actions in Biology.Neurochemical research · 2026Review
- AARS1-mediated lactylation of H3K18 and STAT1 promotes ferroptosis in diabetic nephropathy.Cell death and differentiation · 2026Article
- Novel progress in the application of the small molecule drug carnosine for the treatment of several diseases (Review).International journal of molecular medicine · 2025Review
- Histidine-Containing Dipeptides in Obesity and Cardiometabolic Health: A Systematic Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Article
- A comprehensive review on physiological and biological activities of carnosine: turning from preclinical facts to potential clinical applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Carnosine and Beta-Alanine Supplementation in Human Medicine: Narrative Review and Critical Assessment.Nutrients · 2023Review
- Anserine and Carnosine Induce HSP70-Dependent HAntioxidants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivation of the transforming growth factor beta (TGF-β) pathway is a significant contributor to the pathogenesis of diabetic nephropathy. Carnosine is a dipeptide that can inhibit TGF-β synthesis. We tested the hypothesis that carnosine supplement added to standard therapy will result in reduced urinary TGF-β levels among patients with diabetic nephropathy.
methodsWe randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks. Urinary TGF-β level was determined using ELISA, urine albumin was ascertained by immunonephelometric assay, and renal function and metabolic profiles were determined at baseline and during 12 weeks of active treatment. Primary outcome was decrease in urinary levels of TGF-β.
resultsThe 2 groups were comparable for baseline characteristics, blood pressure, urine albumin, urine TGF-β and renal function measurements. Urinary TGF-β significantly decreased with carnosine supplement (- 17.8% of the baseline values), whereas it tended to increase with placebo (+ 16.9% of the baseline values) (between-group difference P < 0.05). However, blood urea nitrogen, serum creatinine, glomerular filtration rate and other biochemical parameters remained unchanged during the study period including urinary albuminuria. Both groups were well tolerated with no serious side-effects.
conclusionsThese data indicated an additional renoprotective effect of oral supplementation with carnosine to decrease urinary TGF-β level that serves as a marker of renal injury in diabetic nephropathy.
trial registrationThai Clinical Trials, TCTR20200724002 . Retrospectively Registered 24 July 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.